Acurx Pharmaceuticals Reports Q2 2026 Results and Business Update
Acurx Pharmaceuticals announced its second quarter 2026 financial results and provided a business update. The company is developing a new class of antibiotics for difficult-to-treat bacterial infections.
STATEN ISLAND, N.Y., Aug. 14, 2026 – Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) today announced its financial results for the second quarter of 2026 and provided an update on its business operations.
The company is focused on developing a new class of antibiotics designed to combat difficult-to-treat bacterial infections. This development is critical in an era of increasing antibiotic resistance.
Further details regarding the quarter's financial performance and the progress of clinical programs are expected to be disclosed in the company's forthcoming reports. Acurx's approach aims to provide alternatives to existing treatments to which bacteria have developed resistance.
For the remainder of 2026, Acurx anticipates continuing to advance its key clinical trials and preparing for potential future regulatory submissions. The company's long-term objective is to bring new therapies to market to address significant unmet medical needs.